The popularity of Ozempic shots, also known as GLP-1 receptor agonists, has soared due to their effectiveness in weight loss and managing type 2 diabetes. However, the idea of oral GLP-1 pills has not gained as much traction. While these pills offer convenience and accessibility compared to injections, various obstacles have hindered their widespread acceptance.
One major setback for oral GLP-1 medications was Pfizer’s decision to discontinue clinical trials of its oral GLP-1 drug, danuglipron, after a study participant experienced a liver injury potentially linked to the experimental medication. Additionally, Novo Nordisk’s semaglutide pill, Rybelsus, has not received as much attention as its injectable counterparts, such as Ozempic and Wegovy, which are primarily used for type 2 diabetes treatment.
Despite the lack of FDA-approved oral GLP-1 drugs for weight loss, early clinical trials have shown promising results. For instance, participants who took oral semaglutide in a study lost an average of 15 percent of their body weight, compared to just 2.4 percent in the placebo group. These findings suggest that oral GLP-1 medications could be as effective as injectable forms in promoting weight loss.
One of the challenges of oral GLP-1 drugs is ensuring their potency and effectiveness, as they must pass through the gastrointestinal tract without being broken down. Rybelsus, for example, contains a special molecule that aids in its absorption through the stomach lining. While some medication may break down, enough of it reaches the bloodstream to result in health benefits. To maximize effectiveness, manufacturers recommend taking the pill on an empty stomach and waiting 30 minutes before eating.
Like their injectable counterparts, GLP-1 pills can cause gastrointestinal side effects. In clinical trials, participants experienced issues such as nausea, vomiting, and diarrhea. Despite these drawbacks, the potential health benefits of oral GLP-1 drugs, such as reduced risk of heart attack and stroke, make them a promising option for weight loss and diabetes management.
Eli Lilly is also developing an oral GLP-1 drug, orforglipron, which is showing promising results in clinical trials for both type 2 diabetes and obesity. Early data suggests that participants can lose between 10 and 15 percent of their body weight after taking the drug for 36 weeks. Additionally, orforglipron has been effective in lowering blood glucose levels in people with type 2 diabetes.
In conclusion, while oral GLP-1 medications have faced challenges in gaining popularity, ongoing research and development efforts show promise for their effectiveness in weight loss and managing diabetes. With continued advancements and improvements, oral GLP-1 drugs could provide a more convenient and accessible option for individuals seeking to improve their health and well-being. Eli Lilly is making strides in the pharmaceutical world with plans to kickstart the review process for regulatory approval of orforglipron in 2025 for weight loss and in 2026 for type 2 diabetes. This announcement comes on the heels of Pfizer halting the trial of its oral drug, a move that has sparked conversation within the industry.
In response to inquiries about Pfizer’s decision, a company spokesperson directed Scientific American to the press release detailing the termination of the trial. Pfizer is now focusing on the development of other early-stage oral drug candidates for weight loss, including one that targets a hormone similar to GLP-1, currently undergoing phase 2 clinical trials.
Dr. Srinath, a healthcare professional, believes that the introduction of more forms of GLP-1 medication is beneficial as it provides patients with a wider range of treatment options. Additionally, oral pills are generally more cost-effective for pharmaceutical companies to produce compared to injectable medications, potentially leading to lower costs for consumers.
However, the emergence of new oral drugs also raises important questions. Dr. Cavender highlights concerns regarding dosing strategies for different pills and how this may impact individuals with multiple health conditions. Finding the optimal method of administering GLP-1 pills in various scenarios is crucial for ensuring effective treatment outcomes.
As Eli Lilly moves forward with the regulatory approval process for orforglipron, the pharmaceutical industry eagerly anticipates the potential benefits that this new medication may bring for individuals struggling with weight loss and type 2 diabetes. Stay tuned for updates on this groundbreaking development in the field of healthcare.
